Refine your search�ソスF     
Report No.
 - 

Production of no-carrier-added $$^{177}$$Lu via the $$^{176}$$Yb(n,$$gamma$$)$$^{177}$$Yb$$rightarrow$$$$^{177}$$Lu process

Hashimoto, Kazuyuki; Matsuoka, Hiromitsu; Uchida, Shoji*

The $$beta^{-}$$ emitter $$^{177}$$Lu is a promising therapeutic radioisotope for the treatment of cancer. It has a half-life of 6.73 days and maximum $$beta^{-}$$ energy of 498 keV, resulting in a short range of radiation in tissue. The decay is accompanied by the emission of low energy $$gamma$$-radiation with $$E_{gamma}$$ = 208 keV (11.0%) and 113 keV (6.4%) suitable for simultaneous imaging. Lutetium-177 can be usually produced at nuclear reactors with high yield and high specific radioactivity by the $$^{176}$$Lu(n,$$gamma$$)$$^{177}$$Lu reaction. However, radioisotopes with higher specific radioactivity are required in the field of radioimmunotherapy using labeled monoclonal antibodies. Thus, an alternative production route, namely the $$^{176}$$Yb(n,$$gamma$$)$$^{177}$$Yb $$rightarrow$$ $$^{177}$$Lu process was studied to produce no-carrier-added (nca) $$^{177}$$Lu in this work. The radiochemical separation of the nca $$^{177}$$Lu from the macroscopic ytterbium target was investigated by means of reversed-phase ion-pair HPLC. The nca $$^{177}$$Lu was obtained in radiochemical pure form with a separation yield of 80%.

Accesses

:

- Accesses

InCites™

:

Percentile:91.54

Category:Chemistry, Analytical

Altmetrics

:

[CLARIVATE ANALYTICS], [WEB OF SCIENCE], [HIGHLY CITED PAPER & CUP LOGO] and [HOT PAPER & FIRE LOGO] are trademarks of Clarivate Analytics, and/or its affiliated company or companies, and used herein by permission and/or license.